The public health risk posed by allergy has been largely underestimated, the underlying common fallacy being that it is just a mild disease. Yet, as you are well aware, allergy is a public health concern of pandemic proportions, affecting today more than 150 million people in Europe and wreaking far-reaching damage in terms of both human suffering and economic burden.
Although important steps have been taken at the EU level by integrating allergy in the EU’s public health agenda, lack of concerted action and lack of realization on both the true risks of allergic diseases and the preventive treatments that can stop their progression still hold sway. As a result, the quality of life of millions of Europeans and their families is impaired while the financial burden of health care and loss in productivity is continuously growing.
On the occasion of the centenary of the first scientific publication on allergy’s signature treatment, ‘allergen-specific immunotherapy’ (1911-2011), EAACI prepared a pivotal document: A ‘European Declaration on Immunotherapy’, which was co-signed by EFA, the European Federation of Allergy and Airway Diseases Patient Associations, and GA2LEN, an EU-supported Network of Excellence. Its purpose is to raise awareness of the detrimental impact of allergy on Europe and to suggest specific actions designed to face this growing problem effectively.
The Declaration was launched 13 June 2011, on the occasion of the
EAACI General Assembly during the 30th EAACI Congress in Istanbul.
Immunotherapy Declaration in
EnglishImmunotherapy Declaration in
PolishImmunotherapy Declaration in
RussianImmunotherapy Declaration in
Turkish Immunotherapy Declaration in
Lithuanian Immunotherapy Declaration in
Spanish Immunotherapy Declaration in
ItalianImmunotherapy Declaration in
DutchImmunotherapy Declaration in
GreekImmunotherapy Declaration in
Portuguese |
